I hereby certify that this correspondence is being deposited with the United States Postal Service as first class mail in an envelope addressed to:

Attorney Docket No.: 02307K-059110US

Client Ref. No.: 95-199-2

**Assistant Commissioner for Patents** 

Washington, D.C. 20231

on Upill 2, Decel

TOWNSEND and TOWNSEND and CREW LLP

Vita Z

## IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re application of:

William M. Kavanaugh et al.

Application No.: 09/894,967

Filed: June 27, 2001

For: BINDING SITES FOR

PHOSPHOTYROSINE BINDING

**DOMAINS** 

Examiner:

Not Yet Assigned

Art Unit:

Not Yet Assigned

**COMMUNICATION** 

Box Sequence P.O. Box 2327 Arlington VA, 22202

Sir:

In response to the Notice To Comply With Requirements For Patent Applications Containing Nucleotide Sequence And/Or Amino Acid Sequence Disclosures, mailed March 15, 2002, please find enclosed a replacement copy of the computer-readable form of Sequence Listing originally filed October 29, 2001.

## **REMARKS**

The Notice To Comply With Requirements For Patent Applications Containing Nucleotide Sequence And/Or Amino Acid Sequence Disclosures, mailed March 15, 2002, stated that the original copy of the computer-readable form of the

William M. Cavanaugh et al. Application No.: 09/894,967 Page 2

Sequence Listing filed October 29, 2001 was damaged due to treatment given to all incoming mail.

Applicants have enclosed a replacement copy of the computer-readable for of the sequence listing which is identical in content to the paper copy of the Sequence Listing filed October 29, 2001.

If the Examiner believes a telephone conference would expedite prosecution of this application, please telephone the undersigned at 650-326-2400.

Respectfully submitted,

Andrew T. Serafini Reg. No. 41,303

TOWNSEND and TOWNSEND and CREW LLP Two Embarcadero Center, 8<sup>th</sup> Floor

San Francisco, California 94111-3834

Tel: (415) 576-0200 Fax: (415) 576-0300

ATS:adm PA 3211952 v1

0300

Please type a plus sign (+) inside this box -> +

PTO/SB/21 (08-00) Approved for use inrough 10/31/2002. OMB 0651-0031

April 2, 2002

Date

<i></i>		Application Number Filing Date First Named Inventor		09/894,967  June 27, 2001  William Michael Kavanaugh		
TRANSMITTAL FORM  (to be used for all correspondence after initial filing)  Total Number of Pages in This Submission 1						
						Group
			Exami	ner Name	Not yet assigned	
			Attorne	ey Docket Number	02307K-059110US	
					ENCLO	OSURES
Fee Transmittal Fe	Fee Transmittal Form		Assignment Papers (for an Application)		After Allowance Communication to Group	
Fee Attached		☐ Drawing(s)			Appeal Communication to Board of Appeals and Interferences	
Amendment / Response		Licensing-related Papers		d Papers	Appeal Communication to Group (Appeal Notice, Brief, Reply Brief)	
After Final		Petition Routing Slip (PTO/SB/69) and Accompanying Petition		•	Proprietary Information	
Affidavits/declaration(s)		Petition to Convert to a Provisional Application			Status Letter	
Extension of Time Request		Power of Attorney, Revocation Change of Correspondence Address			Other Enclosure(s)  (please identify below)	
Express Abandonment Request Request Information Disclosure Statement		Termin	Terminal Disclaimer		Copy of Notice to Comply	
		Request for Refund			Communication	
					Sequence List (in CRF)	
		CD, Number of CD(s)		CD(5)	Return Postcard	
Certified Copy of Priority Document(s)		Remarks The Commissioner is Deposit Account 20-1		1	s authorized to charge any additional fees t 1430.	
Response to Miss				J		
Response to Missing Parts under 37 CFR 1.52 or 1.53						
	SIGNA	TURE OF	APPLIC	ANT, ATTORNEY,	OR AGENT	
Firm	Townsend and Townsend and Crew LLP					
and Individual name	Andrew T. Serafini, Ph.D. Reg. No. 41,303					
Signature	Andre V. Engli					
Date	April 2, 2002					
	<u> </u>	CE	RTIFICA	ATE OF MAILING		
hereby certify that th	is correspondence is ope addressed to: A	s being depo ssistant Con	sited with	n the United States Por er for Patents, Washing	stal Service with sufficient postage as first gton, D.C. 20231 on this date:  April 2, 2002	

Burden Hour Statement: This form is estimated to take 0.2 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be send to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

Patents, Washington PA 3212392 v1

Signature



## United States Patent and Trademark Office

COMM SSIONER FOR PATENTS
UNITED STATES PATENT AND TRADEMARK OFFICE
Washington, D.C. 20231
www.uspto.gov

APPLICATION NUMBER FILING RECEIPT DATE FIRST NAMED APPLICANT ATTORNEY DOCKET NUMBER 09/894,967 06/27/2001 William Michael Kavanaugh 02307K-059110US

20350 TOWNSEND AND TOWNSEND AND CREW, LLP TWO EMBARCADERO CENTER EIGHTH FLOOR SAN FRANCISCO, CA 94111-3834 CONFIRMATION NO. 4693 FORMALITIES LETTER

\*OC0000007651894\*

Date Mailed: 03/15/2002

## NOTICE TO COMPLY WITH REQUIREMENTS FOR PATENT APPLICATIONS CONTAINING NUCLEOTIDE SEQUENCE AND/OR AMINO ACID SEQUENCE DISCLOSURES

Applicant is given TWO MONTHS FROM THE DATE OF THIS NOTICE within which to file the items indicated below to avoid abandonment. Extensions of time may be obtained under the provisions of 37 CFR 1.136(a).

• The computer readable form that has been filed with this application has been found to be damaged and/or unreadable as indicated on the attached CRF Diskette Problem Report. A substitute computer readable form must be submitted as required by 37 C.F.R. 1.825(d). Applicant must provide a substitute computer readable form (CRF) copy of the "Sequence Listing" and a statement that the content of the sequence listing information recorded in computer readable form is identical to the written (on paper or compact disc) sequence listing and, where applicable, includes no new matter, as required by 37 CFR 1.821(e), 1.821(f), 1.821(g), 1.825(b), or 1.825(d). If applicant desires the sequence listing in the instant application to be identical with that of another application on file in the U.S. Patent and Trademark Office, such request in accordance with 37 CFR 1.821(e) may be submitted in lieu of a new CRF.

For questions regarding compliance to these requirements, please contact:

- For Rules Interpretation, call (703) 308-4216
- = To Purchase Patentin Software, call (703) 306-2600
- For Patentin Software Program Help, call (703) 306-4119 or e-mail at patin21help@uspto.gov or patin3help@uspto.gov

A copy of this notice MUST be returned with the reply.

Customer Service Center

Initial Patent Examination Division (703) 308-1202

PART 1 - ATTORNEY/APPLICANT COPY